{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:01:53Z","timestamp":1783018913940,"version":"3.54.6"},"reference-count":17,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRP"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>177Lu-Dotatate is used in the treatment of somatostatin-receptor-positive inoperable\nprogressive gastroenteropancreatic neuroendocrine tumors. A co-infusion of amino acids\n(AAs) is administered to prevent renal toxicity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study aimed to quantify the impact of two types of AA cocktails on the pharmacokinetics\nand toxicity of 177Lu-Dotatate.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>Four injections of 7400 MBq 177Lu-Dotatate were given per patient with administration\nof either Primene\u00ae 10% (containing a cocktail of 20 AAs with 22g of Lysine and 16.8 g of\nArginine) or Lysakare\u00ae (containing 25 g of Lysine and 25 g of Arginine). Nine blood samples were\ncollected at each cycle. Radioactivity-time data were analyzed according to a population-based\nmodel using NONMEM (version 7.4.1). Renal and hematological toxicity was evaluated after each\ncycle.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Result:<\/jats:title>\n<jats:p>1,678 177Lu-Dotatate plasma concentrations versus time were analyzed from 83 consecutive\npatients with Primene\u00ae (n= 45 pts) or Lysakare\u00ae (n= 36 pts). Population pharmacokinetic analysis\nshowed that Primene\u00ae significantly increased the elimination rate constant of 177Lu-Dotatate as\nopposed to Lysakare\u00ae. Primene\u00ae also significantly lowered Lutathera\u00ae plasma exposure (AUC) by\n34%, whereas Lysakare\u00ae increased AUC by 7%. There was no renal toxicity in either case. Lymphopenia\nsignificantly correlated with AUC (p=0.021) with a trend towards higher toxicity with\nLysakare\u00ae.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions::<\/jats:title>\n<jats:p>Unlike Primene\u00ae, Lysakare\u00ae does not increase 177Lu-Dotatate elimination. This difference\nis associated with a significant impact on AUC. The latter parameter has a high interpatient\nvariability but a low intrapatient variability, which could have important clinical implications for\ntreatment tailoring.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874471015666211228123525","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T04:24:03Z","timestamp":1643775843000},"page":"164-172","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of Two Types of Amino Acid Solutions on 177Lu-Dotatate\nPharmacokinetics and Pharmacodynamics in Patients with Metastatic Gastroenteropancreatic\nNeuroendocrine Tumors"],"prefix":"10.2174","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7740-9096","authenticated-orcid":true,"given":"Etienne","family":"Chatelut","sequence":"first","affiliation":[{"name":"Department of Pharmacologie, Institut Claudius-Regaud, Institut Universitaire du Cancer Toulouse - Oncopole;\nCRCT, Cancer Research Center of Toulouse, Inserm U1037, Universit\u00e9 Paul Sabatier, 1 avenue Ir\u00e8ne Joliot-Curie\nF-31059 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Pharmacologie, Institut Claudius-Regaud, Institut Universitaire du Cancer Toulouse - Oncopole;\nCRCT, Cancer Research Center of Toulouse, Inserm U1037, Universit\u00e9 Paul Sabatier, 1 avenue Ir\u00e8ne Joliot-Curie\nF-31059 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-4138","authenticated-orcid":true,"given":"Lawrence","family":"Dierickx","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Institut Universitaire du Cancer Toulouse - Oncopole,\nToulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-7600","authenticated-orcid":true,"given":"S\u00e9verine","family":"Brillouet","sequence":"additional","affiliation":[{"name":"Department of Radiopharmacy, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse,\nFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Courbon","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Institut Universitaire du Cancer Toulouse - Oncopole,\nToulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"Strosberg J.","year":"2017","unstructured":"Strosberg J.; El-Haddad G.; Wolin E.; Hendifar A.; Yao J.; Chasen B.; Mittra E.; Kunz P.L.; Kulke M.H.; Jacene H.; Bushnell D.; O\u2019Dorisio T.M.; Baum R.P.; Kulkarni H.R.; Caplin M.; Lebtahi R.; Hobday T.; Delpassand E.; Van Cutsem E.; Benson A.; Srirajaskanthan R.; Pavel M.; Mora J.; Berlin J.; Grande E.; Reed N.; Seregni E.; \u00d6berg K.; Lopera Sierra M.; Santoro P.; Thevenet T.; Erion J.L.; Ruszniewski P.; Kwekkeboom D.; Krenning E.; Phase 3 trial of Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017,376(2),125-135","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","volume":"30","author":"Kwekkeboom D.J.","year":"2003","unstructured":"Kwekkeboom D.J.; Bakker W.H.; Kam B.L.; Teunissen J.J.M.; Kooij P.P.M.; de Herder W.W.; Feelders R.A.; van Eijck C.H.J.; de Jong M.; Srinivasan A.; Erion J.L.; Krenning E.P.; Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003,30(3),417-422","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00259-015-3250-z","volume":"43","author":"Bodei L.","year":"2016","unstructured":"Bodei L.; Kidd M.; Modlin I.M.; Severi S.; Drozdov I.; Nicolini S.; Kwekkeboom D.J.; Krenning E.P.; Baum R.P.; Paganelli G.; Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2016,43(5),839-851","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00259-006-0232-1","volume":"34","author":"Rolleman E.J.","year":"2007","unstructured":"Rolleman E.J.; Krenning E.P.; Bernard B.F.; de Visser M.; Bijster M.; Visser T.J.; Vermeij M.; Lindemans J.; de Jong M.; Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats. Eur J Nucl Med Mol Imaging 2007,34(2),219-227","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00259-010-1685-9","volume":"38","author":"Vegt E.","year":"2011","unstructured":"Vegt E.; Melis M.; Eek A.; de Visser M.; Brom M.; Oyen W.J.G.; Gotthardt M.; de Jong M.; Boerman O.C.; Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging 2011,38(4),623-632","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00259-003-1117-1","volume":"30","author":"Jamar F.","year":"2003","unstructured":"Jamar F.; Barone R.; Mathieu I.; Walrand S.; Labar D.; Carlier P.; de Camps J.; Schran H.; Chen T.; Smith M.C.; Bouterfa H.; Valkema R.; Krenning E.P.; Kvols L.K.; Pauwels S.; 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003,30(4),510-518","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/bjc.1993.266","volume":"67","author":"Hammond P.J.","year":"1993","unstructured":"Hammond P.J.; Wade A.F.; Gwilliam M.E.; Peters A.M.; Myers M.J.; Gilbey S.G.; Bloom S.R.; Calam J.; Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993,67(6),1437-1439","journal-title":"Br J Cancer"},{"key":"ref=8","first-page":"829","volume":"37","author":"Behr T.M.","year":"1996","unstructured":"Behr T.M.; Becker W.S.; Sharkey R.M.; Juweid M.E.; Dunn R.M.; Bair H.J.; Wolf F.G.; Goldenberg D.M.; Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 1996,37(5),829-833","journal-title":"J Nucl Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-018-0674-1","volume":"58","author":"Puszkiel A.","year":"2019","unstructured":"Puszkiel A.; Bauriaud-Mallet M.; Bourgeois R.; Dierickx L.; Courbon F.; Chatelut E.; Evaluation of the interaction of amino acid infusion on Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Clin Pharmacokinet 2019,58(2),213-222","journal-title":"Clin Pharmacokinet"},{"key":"ref=10","unstructured":"Summary of product characteristics: Lutathera. Available from:  (Accessed on April 27, 2021)."},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph12030114","volume":"12","author":"Hennrich U.","year":"2019","unstructured":"Hennrich U.; Kopka K.; Lutathera: The first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel) 2019,12(3),114","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"Bergstrand M.","year":"2011","unstructured":"Bergstrand M.; Hooker A.C.; Wallin J.E.; Karlsson M.O.; Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011,13(2),143-151","journal-title":"AAPS J"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s00259-009-1282-y","volume":"37","author":"Rolleman E.J.","year":"2010","unstructured":"Rolleman E.J.; Melis M.; Valkema R.; Boerman O.C.; Krenning E.P.; de Jong M.; Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010,37(5),1018-1031","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","volume":"51","author":"Vegt E.","year":"2010","unstructured":"Vegt E.; de Jong M.; Wetzels J.F.M.; Masereeuw R.; Melis M.; Oyen W.J.G.; Gotthardt M.; Boerman O.C.; Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010,51(7),1049-1058","journal-title":"J Nucl Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0969-8051(01)00241-4","volume":"28","author":"Akizawa H.","year":"2001","unstructured":"Akizawa H.; Arano Y.; Mifune M.; Iwado A.; Saito Y.; Mukai T.; Uehara T.; Ono M.; Fujioka Y.; Ogawa K.; Kiso Y.; Saji H.; Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides. Nucl Med Biol 2001,28(7),761-768","journal-title":"Nucl Med Biol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00259-014-2928-y","volume":"42","author":"Hicks R.J.","year":"2015","unstructured":"Hicks R.J.; The difference between medicine and magic is that magicians know what they are doing. Eur J Nucl Med Mol Imaging 2015,42(1),1-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-74579-4","author":"Stabin M.G.","year":"2008","unstructured":"Stabin M.G.;  Fundamentals of Nuclear Medicine Dosimetry 2008","journal-title":"Fundamentals of Nuclear Medicine Dosimetry"}],"container-title":["Current Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874471015666211228123525","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/199553\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874471015666211228123525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T16:32:25Z","timestamp":1666888345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/199553\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874471015666211228123525","relation":{},"ISSN":["1874-4710"],"issn-type":[{"value":"1874-4710","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}